334 related articles for article (PubMed ID: 16404802)
1. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
[TBL] [Abstract][Full Text] [Related]
2. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
3. Hyperglycemia and antipsychotic medications.
Haupt DW; Newcomer JW
J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
[TBL] [Abstract][Full Text] [Related]
4. Schizophrenia and comorbid metabolic disorders.
Henderson DC
J Clin Psychiatry; 2005; 66 Suppl 6():11-20. PubMed ID: 16107179
[TBL] [Abstract][Full Text] [Related]
5. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
[TBL] [Abstract][Full Text] [Related]
6. Implementation of monitoring and management guidelines for second-generation antipsychotics.
Sernyak MJ
J Clin Psychiatry; 2007; 68 Suppl 4():14-8. PubMed ID: 17539695
[TBL] [Abstract][Full Text] [Related]
7. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
Baptista T; Kin NM; Beaulieu S; de Baptista EA
Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
[TBL] [Abstract][Full Text] [Related]
8. Long-term health considerations in schizophrenia: metabolic effects and the role of abdominal adiposity.
Van Gaal LF
Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S142-8. PubMed ID: 16863690
[TBL] [Abstract][Full Text] [Related]
9. The comorbidity of diabetes mellitus and psychiatric disorders.
Medved V; Jovanović N; Knapić VP
Psychiatr Danub; 2009 Dec; 21(4):585-8. PubMed ID: 19935498
[TBL] [Abstract][Full Text] [Related]
10. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
Rzewuska M
Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
[TBL] [Abstract][Full Text] [Related]
11. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.
Schneiderhan ME; Batscha CL; Rosen C
Pharmacotherapy; 2009 Aug; 29(8):975-87. PubMed ID: 19637951
[TBL] [Abstract][Full Text] [Related]
12. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
Monteleone P; Martiadis V; Maj M
Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
[TBL] [Abstract][Full Text] [Related]
13. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics.
Meltzer HY
J Clin Psychiatry; 2001; 62 Suppl 27():35-9; discussion 40-1. PubMed ID: 11806488
[TBL] [Abstract][Full Text] [Related]
14. [Atypical antipsychotic induced weight gain and metabolic disorders].
Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
[TBL] [Abstract][Full Text] [Related]
15. Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.
De Hert M; van Eyck D; De Nayer A
Int Clin Psychopharmacol; 2006 Mar; 21 Suppl 2():S11-5. PubMed ID: 16601508
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.
McIntyre RS; Jerrell JM
Arch Pediatr Adolesc Med; 2008 Oct; 162(10):929-35. PubMed ID: 18838645
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
Henderson DC
J Clin Psychiatry; 2001; 62 Suppl 27():10-4; discussion 40-1. PubMed ID: 11806484
[TBL] [Abstract][Full Text] [Related]
18. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer JW
J Clin Psychiatry; 2007; 68 Suppl 1():20-7. PubMed ID: 17286524
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome and mental illness.
Newcomer JW
Am J Manag Care; 2007 Nov; 13(7 Suppl):S170-7. PubMed ID: 18041878
[TBL] [Abstract][Full Text] [Related]
20. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
Newcomer JW
J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]